Anika Therapeutics | ANIK - Sales Revenues

Stock Price
15.15
Daily Change
-0.15 -0.98%
Monthly
5.50%
Yearly
12.47%
Q2 Forecast
14.36

Anika Therapeutics reported $30.62M in Sales Revenues for its fiscal quarter ending in December of 2025.





Sales Change Date
Abbott USD 11.46B 90M Dec/2025
Agenus USD 34.2M 3.97M Dec/2025
Agios Pharmaceuticals USD 19.97M 7.07M Dec/2025
Anika Therapeutics USD 30.62M 2.8M Dec/2025
Arrowhead Research USD 264.03M 7.56M Dec/2025
Enanta Pharmaceuticals USD 16.96M 50.68M Dec/2024
Halozyme Therapeutics USD 451.76M 97.76M Dec/2025
Heron Therapeutics USD 40.59M 2.38M Dec/2025
Insmed USD 263.8M 121.8M Dec/2025
Integra LifeSciences USD 434.9M 32.84M Dec/2025
Intrexon USD 717K 511K Jun/2024
J&J USD 24.1B 500M Mar/2026
Karyopharm Therapeutics USD 34.08M 3.54M Dec/2025
Ligand Pharmaceuticals USD 59.66M 55.8M Dec/2025
MacroGenics USD 41.23M 31.61M Dec/2025
Merit Medical Systems USD 393.9M 9.7M Dec/2025
Rigel Pharmaceuticals USD 55.31M 18.47M Sep/2024
Sangamo BioSciences USD 356K 125K Jun/2024
Sanofi EUR 11.3B 1.13B Dec/2025
Smith & Nephew USD 3.18B 353M Dec/2025
Stryker USD 7.2B 1.14B Dec/2025
Surmodics USD 29.57M 355K Jun/2025
Veracyte USD 140.6M 8.7M Dec/2025
Xencor USD 28.24M 7.24M Dec/2025
Zimmer Biomet Holdings USD 2.24B 240M Dec/2025